Focus: Grifols is a diagnostics and plasma derivatives company headquartered in New York, operating as a publicly traded entity since 1909 with a focus on rare diseases and blood-derived therapies.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Grifols to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic commodity product providing stable but declining revenue base.
Help build intelligence for Grifols
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Grifols's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Plasma machine at Grifols collection centre issued five alerts before Winnipeg donor’s death - The Globe and Mail
Plasma machine at Grifols collection centre issued five alerts before Winnipeg donor’s death The Globe and Mail
Grifols lays the first stone of the new plant in Lliçà de Vall - Diari ARA
Grifols lays the first stone of the new plant in Lliçà de Vall Diari ARA
Family of plasma donor who died calls for investigation over record inconsistencies - The Globe and Mail
Family of plasma donor who died calls for investigation over record inconsistencies The Globe and Mail
The market punishes Grifols despite quarterly profits - Diari ARA
The market punishes Grifols despite quarterly profits Diari ARA
8-K Filing: FrontView REIT, Inc. (FVR) (CIK 0001988494) — EX-99.2
EX-99.2
8-K Filing: QuidelOrtho Corp (QDEL) (CIK 0001906324) — EX-99.1
EX-99.1
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Canadian regulatory sanctions (plasma center deaths, Health Canada inspection deficiencies in March–April 2026) present material operational and reputational risk; potential downstream impact on R&D resourcing.
Recent peer-reviewed publications with author affiliations at this company
Hereditary Antithrombin Deficiency in Pediatric Patients: Pathophysiology, Clinical Features, Diagnosis, and Antithrombin Replacement Therapy.
Efficacy and safety of fibrinogen concentrate (BT524) in severe hemorrhage: Phase 3 subcohort analysis of the AdFIrst trial in patients undergoing cytoreductive surgery for pseudomyxoma peritonei.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo